(NASDAQ: ALMS) Alumis's forecast annual revenue growth rate of -20.73% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 101.28%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.62%.
Alumis's revenue in 2025 is $22,121,000.On average, 10 Wall Street analysts forecast ALMS's revenue for 2025 to be $2,702,849,597, with the lowest ALMS revenue forecast at $2,260,952,322, and the highest ALMS revenue forecast at $2,972,810,937. On average, 10 Wall Street analysts forecast ALMS's revenue for 2026 to be $570,718,734, with the lowest ALMS revenue forecast at $0, and the highest ALMS revenue forecast at $1,411,711,989.
In 2027, ALMS is forecast to generate $1,828,032,880 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $4,385,149,286.